We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A company’s right to challenge a patent that it is licensed to use is not restricted by the licensing agreement between it and the patent holder, the U.S. Supreme Court said in a Jan. 9 ruling.
Merck announced good sales growth for the last quarter of 2006 but noted a major drop in earnings due to special charges and an increase in reserves for future legal costs.
Schering-Plough’s fourth quarter profits for 2006 rose 75 percent from the same time period in 2005, and its net income for the same period was $182 million, up from $104 million in the fourth quarter of 2005, the company announced.
Amgen reported a strong increase in sales for 2006, although the company’s profit for the fourth quarter increased only 1 percent from the same time period in 2005.
Strong pharmaceutical sales helped Johnson & Johnson (J&J) reach a 3.5 percent increase in fourth quarter earnings, even after the major cost of acquiring Pfizer Consumer Healthcare, the company announced.
Pfizer is making major changes in the way the company is run in an effort to drive down costs, increase revenue and enhance innovation, Pfizer announced at a meeting of its senior staff.
GlaxoSmithKline (GSK) will undertake a head-to-head study of its candidate to prevent cervical cancer against Merck’s drug Gardasil in an effort to sway the market, GSK said.
Bristol-Myers Squibb (BMS) reported a net loss from continuing operations of $134 million on sales of $4.2 billion in the fourth quarter of 2006, compared with net earnings of $499 million on sales of $5 billion for the same period in 2005.
Strong pharmaceutical sales helped Johnson & Johnson (J&J) reach a 3.5 percent increase in fourth quarter earnings, even after the major cost of acquiring Pfizer Consumer Healthcare, the company announced.